TICKERNERD
Menu
NRXPNRXPHealthcare · Biotechnology

NRXP Stock Forecast: NRX Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.40
0.00% on the day

The 4 Wall Street analysts covering NRX Pharmaceuticals, Inc. hold a median 12-month price target of $47 — +1282.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$147.2M
Ticker Nerd rank
20 / 100
Median analyst target
$47
Analysts covering
4
Revenue$1.1M
Operating income−$6.5M
Net income−$16.5M
Free cash flow−$9.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.9%
1M
0.0%
YTD
+25.5%
1Y
+18.1%
From 52W high
−26.4%
From 52W low
+102.4%
$1.68
$4.62
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NRXP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NRX Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
72
Momentum
68
Issuance
60
Growth
43
Accruals
31
Revisions
30
Volatility
15
Value
8
Quality
5

Size (72): Smaller than most of the companies we track.

Quality (5): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NRXP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRXP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00$50.00Oct 25Jan 26Apr 26Jul 26NRXPHigh $49Median $47Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $10Median $47High $49

The green dot is the last close — the median target sits +1282.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Aug 2026HC Wainwright & Co.ReiteratesBuy$45
18 Aug 2026BTIGReiteratesBuy$10
7 Aug 2026BTIGMaintainsBuy—
7 Aug 2026BTIGMaintainsBuy$25 → $10
5 May 2026D. Boral CapitalMaintainsBuy—
5 May 2026D. Boral CapitalMaintainsBuy$34
27 Apr 2026Ascendiant CapitalMaintainsBuy—
27 Apr 2026HC Wainwright & Co.ReiteratesBuy—
23 Apr 2026D. Boral CapitalMaintainsBuy—
20 Apr 2026D. Boral CapitalMaintainsBuy—
24 Mar 2026BTIGReiteratesBuy—
24 Mar 2026D. Boral CapitalMaintainsBuy—
17 Mar 2026D. Boral CapitalMaintainsBuy—
16 Mar 2026D. Boral CapitalMaintainsBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—
3 Mar 2026HC Wainwright & Co.MaintainsBuy—
18 Feb 2026BTIGReiteratesBuy—
17 Feb 2026D. Boral CapitalMaintainsBuy—
15 Jan 2026BTIGReiteratesBuy—
5 Jan 2026D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRXP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NRXP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, NRX Pharmaceuticals, Inc. returned +18.1% against +17.5% for the S&P 500, dividends included.

NRXP vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26NRXPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NRXP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−376.9%
Analysts raising
0
Analysts cutting
1
Fundamentals

NRX Pharmaceuticals, Inc. (NRXP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.4×

Cheaper than 72% of US stocks

Price / sales
43.4×

Cheaper than 6% of US stocks

Price / book
−754.1×

Cheaper than 99% of US stocks

EV / EBITDA
−6.1×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
3.1%

Higher than 34% of US stocks

Earnings growth (YoY)
—
Gross margin
38.7%

Higher than 47% of US stocks

Operating margin
−590.5%

Higher than 7% of US stocks

Net margin
58.8%

Higher than 97% of US stocks

Returns & dividend
Return on equity
179.6%

Higher than 98% of US stocks

Return on assets
−64.0%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NRX Pharmaceuticals, Inc. (NRXP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NRX Pharmaceuticals, Inc. has a market value of $147.2M and an enterprise value of $121.2M.

  • Revenue in the twelve months to 30 June 2026: $3.4M. The latest quarter grew 3.1% year on year.

  • Net income over the same four quarters: −$23.5M, a −691.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$20.7M.

  • Shares outstanding: 43.2M.

  • Trailing P/E: 0.4×; forward P/E: 6.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • NRX Pharmaceuticals, Inc. employs 29 people — $117K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

NRXP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NRXPNRX Pharmaceuticals, Inc.$147.2M
20
LENZLENZ Therapeutics, Inc.$141.4M
24
UNCYUnicycive Therapeutics, Inc.$141.2M
35
TNYATenaya Therapeutics, Inc.$138.6M
37
MENSJyong Biotech Ltd.$147.7M
3
CRBUCaribou Biosciences, Inc.$136.2M
57
CRBPCorbus Pharmaceuticals Holdings, Inc.$150.4M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NRX Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NRXP news & analysis

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

GlobeNewsWire · 11 Sept 2026positive

NRx Pharmaceuticals announced that its subsidiary HOPE Therapeutics will be the first Interventional Psychiatry practice to deploy Zeta Surgical's newly FDA-cleared Zeta TMS Robotic System, with clinical staff now in training ahead of deployment in Florida.

Why it matters — This positions HOPE Therapeutics at the forefront of deploying a newly FDA-cleared robotic TMS system, which expands the company's clinical capabilities and service offerings.

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewsWire · 8 Sept 2026neutral

NRx Pharmaceuticals announced that its management team will participate in three investor conferences scheduled for September 2026. The clinical-stage biopharmaceutical company made the announcement on September 8, 2026.

Why it matters — Participation in investor conferences gives NRXP watchers opportunities for the company to present its clinical-stage pipeline and engage directly with investors.

NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript

Seeking Alpha · 18 Aug 2026neutral

NRx Pharmaceuticals, Inc. (NRXP) held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's second-quarter 2026 financial results and business update.

Why it matters — NRXP watchers would care because the earnings call transcript provides direct insight into the company's latest financial performance and management commentary.

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

GlobeNewsWire · 17 Aug 2026positive

NRx Pharmaceuticals reported its second quarter 2026 financial results and provided a corporate update. The company completed the first-cycle FDA review of its ANDA for preservative-free ketamine with no drug-related major deficiencies, and the sole remaining item—a manufacturer's attestation on the vial—has been submitted to the FDA. A conference call is scheduled for Monday, August 17th at 4:30pm ET.

Why it matters — NRXP watchers would care because the ANDA review progress for preservative-free ketamine indicates the company is advancing toward potential FDA approval of a key product.

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 15 Aug 2026negative

NRx Pharmaceuticals reported a Q2 loss of $0.18 per share, wider than the Zacks Consensus Estimate of a $0.09 loss, and missed revenue estimates. The loss improved from $0.98 per share a year earlier.

Why it matters — NRXP watchers would care because the company's second-quarter results came in below analyst expectations on both earnings and revenue, despite narrowing its year-over-year loss.

FAQ

Frequently asked questions about NRXP stock

What is the NRXP stock price forecast for 2026-2027?

The 4 Wall Street analysts covering NRX Pharmaceuticals, Inc. have a median 12-month price target of $47, with estimates ranging from $10 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRXP stock a buy right now?

Of the 4 analysts covering NRX Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NRX Pharmaceuticals, Inc. 20 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRXP?

As at 12 Sept 2026, NRX Pharmaceuticals, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (72 of 100).

Will NRXP stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +1282.4% from the last close, and Ticker Nerd's factor model ranks NRX Pharmaceuticals, Inc. 20 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRXP stock forecast for 2030?

No analyst covering NRX Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $49 over the next 12 months.

How has NRXP stock performed over the past year?

NRX Pharmaceuticals, Inc. returned +18.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NRX Pharmaceuticals, Inc. do?

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suicidal ideation.

What is the latest news on NRXP?

The most recent item we track (GlobeNewsWire, 11 Sept 2026): "NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System". NRx Pharmaceuticals announced that its subsidiary HOPE Therapeutics will be the first Interventional Psychiatry practice to deploy Zeta Surgical's newly FDA-cleared Zeta TMS Robotic System, with clinical staff now in training ahead of deployment in Florida.

Company

About NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suicidal ideation. Its current pipeline centers on NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone. The company also works on adjacent neuropsychiatric and respiratory care initiatives through its broader portfolio and operating segments. NRx Pharmaceuticals, Inc. serves a specialized role in psychiatry by targeting high-unmet-need conditions where conventional treatment options may be limited or insufficient. Headquartered in Wilmington, Delaware, it operates as a focused developer of novel therapeutics for complex mental health and neurological indications.

CEO Dr. Jonathan C. Javitt M.D., M.P.H. · 29 employees · United States · https://www.nrxpharma.com